TheranosticTrials.org

Clinical Trial · NCT05691894

Tracer Targeting FAP PET Imaging in Patients

Overview

This is a single arm study to evaluate the safety and biodistribution of tracer targeting FAP PET Imaging in patients

Sponsor

Affiliated Hospital of Jiangnan University

Phase

Early Phase 1

Contacts

Chunjing Yu (CONTACT)

ycj_wxd1978@163.com

15312238622

Chunjing Yu (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05691894

Drug / Compound

FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules

Eligibility

Inclusion

  • ECOG score 0\~2.
  • At least one measurable solid lesion has been examined according RECIST1.1 standard;
  • Patients diagnosed with cancer confirmed by histopathology or cytology;

Exclusion

  • Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines;
  • Patients who cannot undergo PET/CT imaging scan;
  • Patients with a history of mental illness or related conditions;